Typically, some trials disclose that PD-1 inhibitor has been applied to treat advanced driver-gene-negative nonsquamous NSCLC: one trial discloses that camrelizumab plus carboplatin and pemetrexed prolonged the progression-free survival (PFS) of advanced drive-gene-negative nonsquamous NSCLC patients (12). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.